- Home
- HRMY vs BHC Comparison
HRMY vs BHC Comparison
Compare HRMY & BHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- BHC
- Stock Information
- Founded
- HRMY 2017
- BHC N/A
- Country
- HRMY United States
- BHC Canada
- Employees
- HRMY N/A
- BHC N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- BHC Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- BHC Health Care
- Exchange
- HRMY Nasdaq
- BHC Nasdaq
- Market Cap
- HRMY 2.0B
- BHC 1.7B
- IPO Year
- HRMY 2020
- BHC N/A
- Fundamental
- Price
- HRMY $35.31
- BHC $4.59
- Analyst Decision
- HRMY Strong Buy
- BHC Hold
- Analyst Count
- HRMY 9
- BHC 5
- Target Price
- HRMY $54.22
- BHC $7.20
- AVG Volume (30 Days)
- HRMY 738.5K
- BHC 1.4M
- Earning Date
- HRMY 05-06-2025
- BHC 04-30-2025
- Dividend Yield
- HRMY N/A
- BHC N/A
- EPS Growth
- HRMY 13.13
- BHC N/A
- EPS
- HRMY 2.62
- BHC N/A
- Revenue
- HRMY $744,852,000.00
- BHC $9,731,000,000.00
- Revenue This Year
- HRMY $20.35
- BHC $3.71
- Revenue Next Year
- HRMY $17.42
- BHC $5.03
- P/E Ratio
- HRMY $13.46
- BHC N/A
- Revenue Growth
- HRMY 20.62
- BHC 8.53
- 52 Week Low
- HRMY $26.47
- BHC $3.96
- 52 Week High
- HRMY $41.61
- BHC $9.85
- Technical
- Relative Strength Index (RSI)
- HRMY 61.62
- BHC 38.92
- Support Level
- HRMY $33.47
- BHC $4.41
- Resistance Level
- HRMY $35.35
- BHC $4.57
- Average True Range (ATR)
- HRMY 1.09
- BHC 0.13
- MACD
- HRMY -0.01
- BHC 0.03
- Stochastic Oscillator
- HRMY 70.34
- BHC 19.74
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About BHC Bausch Health Companies Inc.
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.